Form 4: Teladoc Health CFO Mala Murthy Reports Routine Stock Transactions, Including Tax-Related Sale

Teladoc Health's Chief Financial Officer, Mala Murthy, reported the acquisition of shares through vesting of equity awards and a subsequent sale of shares to cover tax withholding obligations.

Summary

• Mala Murthy, Chief Financial Officer of Teladoc Health, Inc. (TDOC), reported multiple transactions involving the company's common stock.
• On May 30, 2025, Ms. Murthy acquired a total of 24,832 shares of common stock through the vesting of performance stock units (2,641 shares) and restricted stock units (2,044, 7,751, 9,233, and 3,163 shares).
• Following these acquisitions, her direct beneficial ownership increased to 146,299 shares.
• On June 2, 2025, Ms. Murthy disposed of 13,856 shares of common stock at a price of $6.86 per share.
• This sale was conducted to cover tax withholding obligations related to the vesting of her performance stock unit and restricted stock unit awards.
• After the sale, Ms. Murthy's direct beneficial ownership stands at 132,443 shares.

Sentiment

Score: 5

Explanation: The document reports routine insider transactions related to executive compensation and tax obligations. It does not contain information that would significantly alter the perception of the company's financial health or strategic direction, thus maintaining a neutral sentiment.

Positives

• The acquisition of 24,832 shares through the vesting of performance and restricted stock units indicates the fulfillment of long-term incentive compensation for the CFO.
• The vesting of these awards demonstrates the company's commitment to its executive compensation plan and aligns management's interests with shareholder value over time.

Negatives

• The sale of 13,856 shares, while routine for tax withholding, represents a reduction in the CFO's direct beneficial ownership of Teladoc Health common stock.

Future Outlook

The document primarily details past and current insider transactions and does not provide specific forward-looking statements or guidance regarding the company's future performance or strategic outlook. It does mention future vesting schedules for equity awards.

Industry Context

This Form 4 filing is a routine disclosure of insider stock transactions, specifically related to equity award vesting and subsequent tax-related sales. Such transactions are common across all industries for executives receiving equity-based compensation and do not inherently reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The routine nature of these transactions is unlikely to have a significant direct impact on shareholders, as they represent standard executive compensation practices. The sale for tax purposes is not indicative of a change in management's confidence.

Next Steps

• Continued vesting of performance stock units: remainder vesting in eight substantially equal quarterly installments after March 1, 2024.
• Continued vesting of restricted stock units (granted June 1, 2022): remainder vesting in eight substantially equal quarterly installments after the first anniversary of the grant date.
• Continued vesting of restricted stock units (granted March 3, 2023): remainder vesting in eight substantially equal quarterly installments after March 1, 2024.
• Continued vesting of certain restricted stock units: remainder vesting in eight substantially equal quarterly installments beginning on June 1, 2025.

Key Dates

Keywords

Teladoc Health, TDOC, SEC Form 4, Insider Transaction, Mala Murthy, Chief Financial Officer, CFO, Stock Vesting, Restricted Stock Units, Performance Stock Units, Equity Awards, Tax Withholding, Beneficial Ownership